SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Wilserdly (giredestrant) is now FDA-approved for ER+, ESR1-mutated advanced breast cancer, offering a new option to help delay disease progression.
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Wilserdly (giredestrant) is now FDA-approved for ER+, ESR1-mutated advanced breast cancer, offering a new option to help delay disease progression.